Solstice Oncology Partner, Hepo Pharmaceuticals, Completes $225 Million Series A Funding to Accelerate Prusabide Monoclonal Antibody in New Adjuvant Cancer Immunotherapy
September 9, 2026Hepo Pharmaceuticals announced that its partner, Solstice Oncology, has successfully raised $225 million in Series A funding to advance the second-generation Fc-enhanced CTLA-4 antibody, Prusabide monoclonal antibody, in the new adjuvant treatment phase for two clinical indications.…
Original URL: Click here to visit original article